MEISi-2

• CAT Number: I031889
• CAS Number: 2250156-71-7
• Molecular Formula: C18H14N2O3
• Molecular Weight: 306.32
• Purity: ≥95%
• Synonyms: 4-hydroxy-N-[(E)-(2-hydroxynaphthalen-1-yl)methylideneamino]benzamide
• InChI: InChI=1S/C18H14N2O3/c21-14-8-5-13(6-9-14)18(23)20-19-11-16-15-4-2-1-3-12(15)7-10-17(16)22/h1-11,21-22H,(H,20,23)/b19-11+
• InChIKey: BBWITAIHTBXEMO-YBFXNURJSA-N
• SMILES: C1=CC=C2C(=C1)C=CC(=C2C=NNC(=O)C3=CC=C(C=C3)O)O

MEISi-2 is a selective inhibitor of MEIS, a key regulator of hematopoietic stem cell (HSC) self-renewal. MEISi-2 is developed for the research of cardiac injuries, hematopoiesis issues, bone marrow transplantations, and cancer[1].
MEISi-2 does not significantly inhibit the PBX-Luc-reporter[1].
MEISi-2 induces MEIS dependent hematopoietic stem cell maintenance and self-renewal[1].
MEISi-2 down-regulates MEIS target gene expression[1].
MEISi-2 induces murine (LSKCD34low cells) and human (CD34+, CD133+, and ALDHhi cells) HSC self-renewal ex vivo[1].
MEISi-2 (10 µM; i.p.; at day 1, day 4 and day 7) functionally inhibits MEIS in vivo, thus they induces c-Kit+ cell, Sca1+ cell, CD150+ cell, LSK HSPCs, LSKCD34low HSC content and LSKCD150+CD48- HSC content[1].
MEISi-2 down-regulates Meis1 expression, Hif-2α, and key CDKI gene expression including p16, p19, p19ARF[1].

Reference

[1]. Raife Dilek Turan, et al. Development of Small Molecule MEIS Inhibitors that modulate HSC activity. Sci Rep. 2020; 10: 7994.
 [Content Brief]